- Home
- BVN vs ABVX Comparison
BVN vs ABVX Comparison
Compare BVN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVN
- ABVX
- Stock Information
- Founded
- BVN 1953
- ABVX 2013
- Country
- BVN Peru
- ABVX France
- Employees
- BVN N/A
- ABVX 69
- Industry
- BVN Metal Mining
- ABVX
- Sector
- BVN Basic Materials
- ABVX
- Exchange
- BVN Nasdaq
- ABVX Nasdaq
- Market Cap
- BVN 6.2B
- ABVX 6.7B
- IPO Year
- BVN 1996
- ABVX N/A
- Fundamental
- Price
- BVN $24.56
- ABVX $86.72
- Analyst Decision
- BVN Hold
- ABVX Strong Buy
- Analyst Count
- BVN 1
- ABVX 9
- Target Price
- BVN $15.50
- ABVX $94.11
- AVG Volume (30 Days)
- BVN 1.5M
- ABVX 969.2K
- Earning Date
- BVN 10-30-2025
- ABVX 08-11-2025
- Dividend Yield
- BVN 1.19%
- ABVX N/A
- EPS Growth
- BVN 436.33
- ABVX N/A
- EPS
- BVN 1.98
- ABVX N/A
- Revenue
- BVN $1,307,905,000.00
- ABVX $7,073,400.00
- Revenue This Year
- BVN $15.88
- ABVX $4.44
- Revenue Next Year
- BVN $8.52
- ABVX N/A
- P/E Ratio
- BVN $12.43
- ABVX N/A
- Revenue Growth
- BVN 32.24
- ABVX N/A
- 52 Week Low
- BVN $11.50
- ABVX $4.77
- 52 Week High
- BVN $25.46
- ABVX $92.91
- Technical
- Relative Strength Index (RSI)
- BVN 75.32
- ABVX 68.69
- Support Level
- BVN $23.83
- ABVX $81.90
- Resistance Level
- BVN $25.40
- ABVX $90.70
- Average True Range (ATR)
- BVN 0.83
- ABVX 2.75
- MACD
- BVN 0.16
- ABVX -0.69
- Stochastic Oscillator
- BVN 83.60
- ABVX 61.24
About BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.